Bulevirtide

Phase 3

Vir Biotechnology, Inc. (VIR)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

VIRPhase 2$1.9B

Bulevirtide Phase 2 Est. Readout

Bulevirtide• Viral Hepatitis100

Nov 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

3 competitors in Viral Hepatitis

View Full Landscape

Drug Information

Target Indication

Viral Hepatitis

Clinical Trial

NCT07142811

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/31/2020

Hepcludex

Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.

OrphanPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

VIR

Vir Biotechnology, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

ElebsiranPhase 3

Viral Hepatitis

VIR-7831 (sotrovimab)Phase 3

Covid19

TobevibartPhase 3

Viral Hepatitis

VIR-2218Phase 2

Hepatitis B, Chronic

pegylated interferon-alfa 2aPhase 2

Chronic Hepatitis B

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts